Panmira appoints chief executive

Hari Kumar will oversee inflammation portfolio

Panmira Pharmaceuticals, a developer of therapies for inflammatory diseases, based in San Diego, California, US, has appointed Hari Kumar as chief executive.

Until recently, Kumar was chief business officer of Amira Pharmaceuticals and led the transaction with Bristol-Myers Squibb for the sale of Amira's fibrosis programme.

Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb.

Kumar and his team will oversee Panmira's inflammation portfolio, which features a CRTH2 programme. The leading candidate, AM211, has demonstrated inhibition of eosinophils over 24 hours following oral, once-daily dosing in Phase I studies.

The firm says CRTH2 antagonists show promise for several diseases including eosinophilic esophagitis, eosinophilic asthma, COPD, and atopic dermatitis.

You may also like

Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Research & Development

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Research & Development

Indena and TCG GreenChem join forces to advance next-generation ADC technologies

Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)
Ingredients

Meet Navetta: new approach to safety testing of drugs and particles

Turn inhalation research upside down
Subscribe now